Executive Chair: Honorary Chair: Professor Anna Maria Geretti Professor Jonathan Weber UCL Medical School, London Imperial College London and University of Liverpool Thursday 29 September 2011 Royal College of Physicians Regent’s Park · London Early Registration Deadline 30 July 2010 6 CPD Credits Unique reference no: 67470 HIV AS A VIROLOGICAL PARADIGM HIV AS A VIROLOGICAL PARADIGM 15th Annual Resistance and Antiviral Therapy Meeting 15th Annual Resistance and Antiviral Therapy Meeting Gold Sponsor Resistance 15th Annual Meeting Resistance 15th Annual Meeting Resistance 15th Annual Meeting FINAL PROGRAMME
12
Embed
Resistance 15 · Introduction Page 3 Programme Page 4,5 Conference Information Page 6,7 Biographies Page 8,9 Sponsors Page 10 Event Diary Page 11 Your delegate badge must be worn
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Executive Chair: Honorary Chair:
Professor Anna Maria Geretti Professor Jonathan WeberUCL Medical School, London Imperial College Londonand University of Liverpool
HIV AS A VIROLOGICAL PARADIGMHIV AS A VIROLOGICAL PARADIGM
Thursday 29 September 2011
Royal College of Physicians · 11 St Andrews Place · Regent’s Park · London NW1 4LE
0815–1545 Registration and exhibition open
0855–0900 IntroductionProfessor Jonathan Weber, Imperial College London
Professor Anna Maria Geretti, University College London Medical Schooland University of Liverpool
The Educational Session
Chair: Dr Mark Atkins, Imperial College Healthcare NHS Trust, London
0900–0930 Hepatitis delta: often forgotten?Dr Sarah Hughes, King’s College Hospital, London
0930–1000 Clinical case: challenges in antiviral therapyDr Sanjay Bhagani, Royal Free Hospital, London
1000–1010 Panel discussion
The Update and Feedback Session
Chairs: Professor Jane Anderson, Homerton University Hospital, London
Chairs: Professor Margaret Johnson, Royal Free Hospital, London
1010–1040 Five papers that have changed clinical practice in 2010–2011Professor Anna Maria Geretti, University College London Medical Schooland University of Liverpool
1040–1050 Discussion
1050–1110 Morning coffee
Plenary Session 1: Antiretroviral drug resistance
Chairs: Dr Marta Boffito, Chelsea and Westminster Hospital, London
Chairs: Professor Jonathan Weber, Imperial College London
1110–1140 PrEP: a drug resistance perspectiveDr Brooke Nichols, Erasmus Medical Centre Rotterdam, The Netherlands
1140–1210 The clinical impact of low-frequency NNRTI-resistant mutantsDr Roger Paredes, University Hospital Germans Trias i Pujol, Barcelona, Spain
1210–1220 Panel discussion
1220–1315 Lunch
The Scientific Committee would like to extend grateful thanks to the Gold Sponsorof this Meeting for providing an educational grant in support of the programme
The registration fee includes access to all scientific sessions, the exhibition areas, lunch andrefreshments throughout the conference.
Continuing Professional Development (CPD)
Medical staff in career-grade posts who are enrolled with one of the Royal Medical Colleges forContinuing Professional Development can receive CPD credits at the rate of one CPD credit perhour (exclusive of travel, refreshments or social activities). The conference has been allocated 6CPD credits with the unique reference code: 67470. Certificates for attendance will be supplied inthe conference pack that will be handed to you at the registration desk.
Scholarships
Community Registration Places have been allocated to delegates attending the conference, on thebasis of a maximum of one free-of-charge registration per community group.
Student Registration Scholarships The conference has supported the registrations of fivedelegates, who are either students or of training grade, to attend the 15th Annual Resistanceand Antiviral Therapy Meeting. These awards were made available to delegates who, throughtheir applications, clearly showed they had financial constraints that would otherwise haveprevented them from attending the conference.
Accommodation
There are a number of hotels near the conference centre offering accommodation. If you requireassistance please contact the Conference Organiser for further details of hotels in the vicinity of theconference venue.
Conference venue
Royal College of Physicians11 St Andrews Place, Regent’s Park, London NW1 4LE
The conference venue is a short walk from Regent’s Park and Great Portland Street Undergroundstations. Please see the map opposite for the location of these stations in relation to the College.
There are also good links to the city centre from both Heathrow and Gatwick airports. Journeysby either Heathrow or Gatwick Express take about an hour.
There are car parks near to the conference venue. Contact the NCP for details.
The conference venue is located outside the London congestion charge zone. The College is in aconvenient and attractive location in the centre of London, easily accessible by all forms oftransport. The main entrance and reception face Regent’s Park.
• Regent’s Park station on theBakerloo line (3 minutes’ walk)
• Great Portland Street station on theCircle, Metropolitan and City lines(5 minutes’ walk)
• Warren Street station on the Victoriaand Northern lines (10 minutes’walk)
By Train:
• Euston station (15 minutes’ walk)
By Air:
• Heathrow: Express train fromHeathrow airport(15 minutes toPaddington station, thenthree stops on theUnderground [Circle Line] to Great Portland Street station)
• Gatwick: Express train from Gatwick airport (30 minutes to Victoria station, then threestops on the Underground [Victoria Line] to Warren Street station)
• Stansted: Express train from Stansted airport (45 minutes to Liverpool Street, then fivestops on the Underground [Circle Line] to Great Portland Street station)
John Ambrose is a PhD student in the Virology Department of University College London Medical School. Hisstudies currently focus on the molecular epidemiology of HIV-1 in high- and low-prevalence settings, withparticular emphasis on recent infection and transmitted drug resistance.
Yusef Azad is Director of Policy at NAT (the National AIDS Trust), the UK’s HIV policy organisation. He hasbeen at NAT since 2004 and previously worked as a parliamentary official, advising and supporting selectcommittee inquiries. In addition to his work at NAT, Yusef co-chairs the EU’s HIV Civil Society Forum, whichadvises the European Commission on HIV policy. He has written, presented and published on a wide range ofHIV issues, such as criminalisation of HIV transmission, equality and discrimination issues, and new approachesto HIV testing.
Sanjay Bhagani is a consultant physician in infectious diseases/HIV medicine and general (internal) medicine atthe Royal Free Hospital, London. He has a sub-specialty interest in managing patients with HIV and hepatitisco-infection and has served on the HIV/hepatitis co-infection management guidelines committees of EACS andBHIVA. He is committed to education and training in HIV medicine for doctors in the developing world and hasbeen involved in delivering training programmes in East Africa and the Indian sub-continent. He is passionateabout fostering further educational links with the developing world.
Francesca Ceccherini-Silberstein is assistant professor to the Chair of Virology, Department of ExperimentalMedicine, University of Rome ‘Tor Vergata’. She obtained her PhD in Biology at the University of Munich inGermany, in 2001. Since 2005, she has been Professor of Virology at the Science Faculty, University of L’Aquila,Italy. Her group undertakes research on HIV/HBV/HCV drug-resistance, HIV pathogenesis, viral tropism, viralevolution, genotypic, structural and functional analysis of viral proteins. She has published 66 full papers inprestigious journals, with an impact factor of >200.
William E Delaney IV is a director in Gilead’s Biology Department where he oversees antiviral discovery researchfor hepatitis B and C viruses. Prior to joining Gilead, Dr Delaney earned his PhD in Cell & Molecular Biologyat the Penn State College of Medicine, Pennsylvania, USA and trained as a postdoctoral fellow with Dr StephenLocarnini at the Victorian Infectious Diseases Reference Laboratory in Melbourne, Australia.
Valerie Delpech is a public health consultant epidemiologist at the Health Protection Agency and has led on thenational surveillance of HIV infections for the United Kingdom for the past 5 years. She trained in medicine andpublic health in Australia and the UK and has extensive experience in communicable disease control and publichealth, with a particular interest in sexual health. Valerie serves on a number of national and internationalcommittees in relation to HIV surveillance, prevention and policy development. She provides scientific supportto the English Expert Advisory Group on AIDS (EAGA) and was a member of the writing committee of the UKNational Guidelines for HIV Testing 2008. Valerie is an executive trustee for the National AIDS Trust. Valerie’sresearch interests and publications have focused on better understanding changes in the epidemiology of HIV,STIs and HIV co-infections, and tracking efforts to curb these epidemics in vulnerable populations.
David Dolling After completing his Masters in Biometry in 2010, David began working as a medical statisticianon the UK HIV Drug Resistance Database at the Medical Research Council’s Clinical Trials Unit in London.
David Dunn is a senior statistician in the HIV Group at the MRC Clinical Trials Unit. Previously he worked at theLondon School of Hygiene and Tropical Medicine in various areas of infectious disease epidemiology and at theInstitute of Child Health where he worked primarily on mother-to-child transmission of HIV and toxoplasmosis.His current interests include antiretroviral drug resistance, therapeutic drug monitoring, the use of laboratorymarkers to monitor HIV infection, and the design and conduct of strategic clinical trials.
Anna Maria Geretti is Professor of Virology & Infectious Diseases and Honorary Consultant at the Institute ofInfection & Global Health, and Visiting Professor at the London Centre for Nanotechnology, University CollegeLondon, where she consults on virus infections, sees patients with HIV or chronic viral hepatitis, teaches andconducts research. She trained in Italy, the Netherlands and the UK, is an elected member of the EACS ExecutiveCommittee, and contributes to educational and scientific activities of EACS, BHIVA, BASHH and IUSTI/ WHO,including the development of practice guidelines. She has edited a book on antiretroviral resistance and publishedover 100 peer-reviewed articles. She enthusiastically shares her expertise to train doctors and scientists, and runscapacity building programmes for resource-limited countries.
Sarah Hughes completed her training at the University of Cambridge Medical School in 1999. She joined theSouth East Thames Specialist Registrar training scheme in Gastroenterology in 2003. She is currently a clinicalresearch Fellow at King’s College Hospital, where she has developed a special interest in hepatitis delta virus. Herresearch, under the supervision of Dr Phil Harrison, is investigating the role of innate immunity in the clearanceof delta virus. She recently published a review on the subject of HDV in The Lancet.
Emma Hodcroft completed her MSc in Quantitative Genetics and Genome Analysis at the University of Edinburgh,graduating with distinction. She now studies the genetic influence of disease progression in HIV with ProfessorAndrew Leigh Brown in Edinburgh and will be beginning her PhD in September to continue this work.
Brooke Nichols is a PhD student in the Department of Virology at the Erasmus Medical Centre in Rotterdam. Aftera Masters degree in Epidemiology at the University of Massachusetts, Amherst, she focused on HIV mathematicalmodelling. She is currently studying the medical prevention of HIV with regard to the development of drugresistance, specifically in the context of test and treat and pre-exposure prophylaxis.
Roger Paredes is attending physician at the HIV Unit, Hospital Universitari Germans Trias i Pujol, in Barcelonaand Head of the Molecular Epidemiology Group at the IrsiCaixa Retrovirology Laboratory. Dr Paredes hasmade key contributions to the current understanding of the clinical relevance of minority HIV-1 resistant variants.
Greg Towers was awarded a BSc (hons) in Biochemistry from the University of Surrey in 1991 and a PhD fromthe University of London in 1995 after working on HIV-1 transcription in the lab of Mary Collins at the Instituteof Cancer Research. He did a post doc at the National Institute of Medical Research with Jonathan Stoye workingon the mouse antiviral protein Fv1. This work continued at the Gene Therapy Institute Genethon in France withOlivier Danos. Greg moved to UCL in 1999 and was awarded a Wellcome RCDF in 2001. During this time hewent on sabbatical to Steve Goff’s lab in Columbia University in New York. Greg is now Professor of MolecularVirology in the Department of Infection at UCL and a Wellcome Senior Research Fellow.
Jonathan Weber trained in Cambridge and, via St Mary’s Hospital Medical School, the Institute of CancerResearch and the Royal Postgraduate Medical School, established the Department of GUM and CommunicableDiseases at Imperial College London, endowed by the Jefferiss Trust, in 1991. This department houses adedicated clinical research facility for HIV and HTLV patients, and was heavily involved in the clinicaldevelopment of combination antiretroviral therapy for the treatment of HIV infection from 1991–1996. Jonathanis the Chair of the Microbicides Development Programme (2001–2011), an MRC/DfID funded project to developa vaginal microbicide, and is the Principal Investigator of the Wellcome Trust funded ‘Spartac’ randomisedclinical trial of short-course therapy at primary HIV infection, which will report in 2011. He is also the ClinicalLead for the EuroVacc Foundation and jointly conducted the EV01, 02 and 03 HIV vaccine DNA/poxprime-boost trials. Jonathan currently leads the Wellcome Trust funded UK HIV Vaccine Consortium.